Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by OttawaPeteron Feb 01, 2023 9:07pm
123 Views
Post# 35261197

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Jannsen Biotech extends its partnership with BTI on xB3!!

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Jannsen Biotech extends its partnership with BTI on xB3!!

Boomskid wrote:
I understand the desire to vote no but we cannot predict with any certainty what Lind will do with a no vote. Lind's rights under the agreements are hard to decipher. Bioasis says it has enough money until March, four weeks away. If Bioasis cannot make a payment on the original Lind loan then the June due date for the promissory notes may have no meaning. Repayment of all Lind loans is due on the EARLIEST of "an event of default" or the June date. It looks to me that a missed payment on the original loan falls within the definition of "an event of default" and may allow Lind to capture the Bioasis assets.
 
Also, there's something fishy about the loans.  If I recall correctly, the $350,000 bridge loan cannot be used for anything other than the legal and other costs associated with the "arrangement." The $510,000 (or whatever) Holiday Note is for the missed payments on the original loan. I question whether Bioasis has already spent most of the Midatech loan. With only a month before March, and with Midatech owing Bioasis a penalty payment of C$300,000 (US$225,000), why does Bioasis have money enough for only into March? Is the $750,000 gone?
 
jd

The voting already closed so people voted how they voted.

The vote does matter-- incompetent DR & BOD "unanimously" approved that deal that only benefitted them.  Does anyone trust them not to continue to screw SHs?  I dont --NO confidence.

loan situation-- definitely fishy & stinks.

<< Previous
Bullboard Posts
Next >>